Core Insights - Clear Medical (01406) reported a revenue of approximately HKD 85 million for the half-year ending in the fiscal year 2026, representing a slight decline of less than 3% compared to the same period last year [1] Group 1: Financial Performance - The company's revenue for the half-year period was approximately HKD 85 million, showing a minor decrease of less than 3% year-on-year [1] - The decline in revenue was attributed to extreme weather conditions that caused the closure or severe disruption of the company's clinics in Hong Kong for eight days during July to September [1] Group 2: Business Challenges - Negative media coverage stemming from allegations made by a former director may have adversely affected the company's business in recent months [1] Group 3: Technological Advancements - The company has strengthened its technological leadership in the Hong Kong ophthalmology market through an exclusive partnership with Johnson & Johnson to introduce the new generation refractive surgery technology, SILK [1] - The SILK technology utilizes low-energy, ultra-precise femtosecond laser pulses, effectively reducing corneal tissue and nerve damage, leading to faster recovery and better postoperative outcomes [1] - Clear Medical plans to promote the SILK technology in the fourth quarter of 2025, being the first and only institution in Hong Kong to offer this technology [1]